Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | CCNC | P24863 | 5/20 | 0.51 |
| ▸ | CDK8 | P49336 | 5/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16150205 | 0.85 | CCNC (0.65) | SIGMAR1CCNCCDK8MKNK1MKNK2 | |
| SCHEMBL12108484 | 0.84 | PROKR1 (0.57) | CCNCCDK8HPGDPROKR1RAB9A | |
| SCHEMBL2386331 | 0.84 | PROKR1 (0.57) | CCNCCDK8HPGDPROKR1RAB9A | |
| SCHEMBL18390549 | 0.83 | POLB (0.54) | MKNK1MKNK2HPGDPROKR1RAB9A | |
| SCHEMBL17714090 | 0.81 | PROKR1 (0.48) | CCNCCDK8PROKR1RAB9ASMN1; SMN2 | |
| SCHEMBL29051582 | 0.80 | SMN1; SMN2 (0.50) | CCNCCDK8PROKR1RAB9ASMN1; SMN2 | |
| SCHEMBL27397141 | 0.80 | PROKR1 (0.47) | CCNCCDK8MKNK1MKNK2PROKR1 | |
| SCHEMBL9104445 | 0.80 | SMN1; SMN2 (0.53) | CCNCCDK8HPGDPROKR1RAB9A | |
| SCHEMBL25848891 | 0.79 | ACHE (0.57) | HPGDPROKR1RAB9ASMN1; SMN2 | |
| SCHEMBL18705999 | 0.78 | SIGMAR1 (0.47) | SIGMAR1CCNCCDK8MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| EP-3380469-B1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11028079-B2 | Small molecule BET bromodomain inhibitors and uses thereof | CONVERGENE, LLC (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200223836-A1 | SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC | 2020-07-16 | — | — | US | disclosed |
| EP-3212638-B1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-20180305344-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY | 2018-10-25 | — | — | US | disclosed |
| EP-3380469-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2018-10-03 | — | — | EP | disclosed |
| US-9796726-B2 | Dihydroquinoline pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796726-B2 | Dihydroquinoline pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3212638-A1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2017-09-06 | — | — | EP | disclosed |
| US-20170226116-A1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226116-A1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-08-10 | — | — | US | disclosed |
| WO-2017091661-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | STROVEL JEFFREY WILLIAM (US) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017091661-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | STROVEL JEFFREY WILLIAM (US) | 2017-06-01 | — | — | WO | disclosed |
| WO-2016066662-A1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016066662-A1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226116-A1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | RECQL, NDUFS5, NDUFS7 | SIGMAR1 433/4885CCNC 636/4885CDK8 791/4885 |
| US-20180305344-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRD3, BRDT | SIGMAR1 4064/4885CCNC 587/4885CDK8 141/4885 |
| US-11028079-B2 | Small molecule BET bromodomain inhibitors and uses thereof | BRDT, BRD4, BRD3 | SIGMAR1 3946/4885CCNC 1201/4885CDK8 201/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | SIGMAR1 4011/4885CCNC 2568/4885CDK8 1863/4885 |
| US-20200223836-A1 | SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF | BRDT, BRD4, BRD3 | SIGMAR1 3946/4885CCNC 1201/4885CDK8 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.